Auxilium and Sobi announce encore presentation of Xiapex data at European Association of urology congress
Thomson Reuters ONE - Mon Apr 14, 5:06AM CDT
- Encore data highlighted from trials evaluating Xiaflex/Xiapex, the first and only FDA approved treatment for Peyronie's Disease.
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A
Thomson Reuters ONE - Thu Apr 10, 6:06AM CDT
- Data showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children under age 12-
Sobi announced as Market Authorisation Holder for Xiapex in 28 EU member countries, Norway and Iceland
M2 - Mon Apr 07, 9:38AM CDT
Biopharmaceutical company Auxilium Pharmaceuticals (NasdaqGS:AUXL) stated on Monday that Swedish Orphan Biovitrum AB (publ) (Sobi) became the Market Authorisation Holder (MAH) for the former's Xiapex (collagenase clostridium histolyticum) in 28 EU member countries, Norway and Iceland on 3 April 2014.
Sobi Becomes Market Authorisation Holder For Xiapex in Europe
PR Newswire - Mon Apr 07, 5:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014.
Sobi becomes market authorisation holder for Xiapex in Europe
Thomson Reuters ONE - Mon Apr 07, 1:02AM CDT
Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex(R) (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014.
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Thu Apr 03, 1:02AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"
Sobi enters partnership with Tigenix for the commercialisation of ChondroCelect
Thomson Reuters ONE - Thu Apr 03, 12:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has acquired the licencing rights to market and distribute ChondroCelect, a cell-based medicinal product for the repair of cartilage defects of the knee, from TiGenix NV (Euronext Brussels: TIG).
Sobi assumes direct responsibility for Orfadin(r) (nitisinone) in US and Canada and introduces Orfadin4U(TM)
GlobeNewswire - Tue Apr 01, 1:08AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today assumed direct responsibility for the distribution of its proprietary product Orfadin in the United States and Canada. Orfadin is the only FDA approved therapy for use as an adjunct to dietary restriction of tyrosine and phenylalanine for the treatment of hereditary tyrosinaemia type 1 (HT-1). Sobi has been responsible for the worldwide development and commercialisation of Orfadin since 1993 and currently distributes the product in over 50 countries around the globe.
Sobi: US FDA approves Alprolix(TM)
GlobeNewswire - Mon Mar 31, 1:05AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Biogen Idec have announced that the US Food and Drug Administration (FDA) has approved Alprolix (Coagulation Factor IX (Recombinant), Fc fusion protein), the first recombinant, DNA derived haemophilia B therapy with prolonged circulation in the body. Alprolix is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia B. The therapy is shown to reduce bleeding episodes with prophylactic (protective) infusions starting at least a week apart.
Sobi: Kiobrina pivotal phase 3 study did not meet primary endpoint
GlobeNewswire - Wed Mar 26, 7:08AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced topline data from the company's pivotal phase 3 study of its enzyme therapy Kiobrina (rhBSSL - recombinant human Bile Salt Stimulated Lipase). The primary endpoint of the study - growth velocity measured after four weeks of treatment with rhBSSL - was not met. No statistically significant improvement in growth velocity was demonstrated in preterm infants treated with rhBSSL compared to placebo.
Cometriq(R) approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Thomson Reuters ONE - Tue Mar 25, 6:01AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved Cometriq(R) (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The European Commission granted conditional marketing authorisation following a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) issued in December 2013. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions.
Health Canada approves Alprolix(TM)
GlobeNewswire - Fri Mar 21, 7:10AM CDT
Swedish Orphan Biovitrum AB's (pupl) (Sobi) partner Biogen Idec today announced that Health Canada has approved Alprolix(TM) (Coagulation Factor IX (Recombinant), Fc fusion protein), rFIXFc, for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with haemophilia B. Alprolix is the first approved long-acting haemophilia B therapy and is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic injections scheduled once weekly or once every 10-14 days.
Can Alexion Pharmaceuticals Continue to Deliver?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development...
Sobi receives EURORDIS Company Award 2014
Thomson Reuters ONE - Wed Feb 26, 1:01AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) was awarded the EURORDIS Company Award 2014 at the EURORDIS Black Pearl Gala Dinner on February 25. The award recognises pioneering companies developing treatments for rare diseases. Sobi was honoured based on the treatments in the company's commercial and development portfolio, on the company's policy and track record on access to drugs, and on its collaboration with patient organisations.
Form 4: Update Filing for Skywest Inc (SKYW)
Vickers Stock Research - Fri Feb 21, 6:41PM CST
The Board of Directors of Swedish Orphan Biovitrum AB (Sobi) has decided to issue an additional nominal amount of up to SEK 200 million under the current bond loan with a loan frame of SEK 1 billion. Sobi has previously issued SEK 600 million in nominal amount under the bond loan which is admitted to trading on NASDAQ OMX Stockholm.